DE60136360D1 - Antigen aus streptococcus pyogenes - Google Patents

Antigen aus streptococcus pyogenes

Info

Publication number
DE60136360D1
DE60136360D1 DE60136360T DE60136360T DE60136360D1 DE 60136360 D1 DE60136360 D1 DE 60136360D1 DE 60136360 T DE60136360 T DE 60136360T DE 60136360 T DE60136360 T DE 60136360T DE 60136360 D1 DE60136360 D1 DE 60136360D1
Authority
DE
Germany
Prior art keywords
antigen
streptococcus pyogenes
streptococcus
prophylaxis
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60136360T
Other languages
German (de)
English (en)
Inventor
Denis Martin
Josee Hamel
Bernard Brodeur
Stephane Rioux
Martine Boyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ID Biomedical Corp of Quebec
Original Assignee
ID Biomedical Corp of Quebec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ID Biomedical Corp of Quebec filed Critical ID Biomedical Corp of Quebec
Application granted granted Critical
Publication of DE60136360D1 publication Critical patent/DE60136360D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60136360T 2000-07-06 2001-07-06 Antigen aus streptococcus pyogenes Expired - Lifetime DE60136360D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21646500P 2000-07-06 2000-07-06
PCT/CA2001/001001 WO2002004495A2 (en) 2000-07-06 2001-07-06 Streptococcus pyogenes antigen

Publications (1)

Publication Number Publication Date
DE60136360D1 true DE60136360D1 (de) 2008-12-11

Family

ID=22807177

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60136360T Expired - Lifetime DE60136360D1 (de) 2000-07-06 2001-07-06 Antigen aus streptococcus pyogenes

Country Status (10)

Country Link
US (2) US7247308B2 (enExample)
EP (1) EP1297145B1 (enExample)
JP (1) JP4718099B2 (enExample)
AT (1) ATE412750T1 (enExample)
AU (1) AU7227001A (enExample)
BR (1) BR0112497A (enExample)
CA (1) CA2413576C (enExample)
DE (1) DE60136360D1 (enExample)
ES (1) ES2316458T3 (enExample)
WO (1) WO2002004495A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7227001A (en) * 2000-07-06 2002-01-21 Shire Biochem Inc Streptococcus pyogenes antigens
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
DE60134494D1 (de) * 2000-12-21 2008-07-31 Id Biomedical Corp Antigene aus streptococcus pyogenes und zugehörige dna-fragmente
WO2004018646A2 (en) * 2002-08-26 2004-03-04 Chiron Corporation Conserved and specific streptococcal genomes
PT1648500E (pt) 2003-07-31 2014-10-10 Novartis Vaccines & Diagnostic Composições imunogénicas para estreptococos piogenes
WO2005017093A2 (en) * 2003-08-15 2005-02-24 Id Biomedical Corporation Polypeptides of streptococcus pyogenes
US8945589B2 (en) * 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
US20090317420A1 (en) * 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
US7838010B2 (en) * 2004-10-08 2010-11-23 Novartis Vaccines And Diagnostics S.R.L. Immunogenic and therapeutic compositions for Streptococcus pyogenes
GB2428006A (en) * 2005-07-07 2007-01-17 Jevgenis Morov AMI-3 vaccine comprising group A Streptococcus pyogenes bacteria
DK2054431T3 (da) * 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
CA2668018A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
US8287885B2 (en) 2007-09-12 2012-10-16 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
AU2008339551B2 (en) 2007-12-21 2013-10-24 Glaxosmithkline Biologicals S.A. Mutant forms of streptolysin O
AU2012271336B2 (en) 2011-06-17 2017-03-02 University Of Tennessee Research Foundation Group A streptococcus multivalent vaccine
AU2014214613A1 (en) 2013-02-11 2015-08-13 University Of Tennessee Research Foundation Group A streptococcal M-related proteins and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0916726A1 (en) * 1997-11-13 1999-05-19 Rijksuniversiteit te Groningen Attaching substances to micro-organisms
AU7227001A (en) 2000-07-06 2002-01-21 Shire Biochem Inc Streptococcus pyogenes antigens

Also Published As

Publication number Publication date
JP4718099B2 (ja) 2011-07-06
US7247308B2 (en) 2007-07-24
JP2004502446A (ja) 2004-01-29
EP1297145B1 (en) 2008-10-29
ATE412750T1 (de) 2008-11-15
EP1297145A2 (en) 2003-04-02
WO2002004495A3 (en) 2002-06-13
CA2413576A1 (en) 2002-01-17
WO2002004495A2 (en) 2002-01-17
AU7227001A (en) 2002-01-21
US20030165528A1 (en) 2003-09-04
US20080038268A1 (en) 2008-02-14
ES2316458T3 (es) 2009-04-16
CA2413576C (en) 2012-11-13
US7811585B2 (en) 2010-10-12
BR0112497A (pt) 2003-11-25

Similar Documents

Publication Publication Date Title
BE2021C506I2 (enExample)
ATE412750T1 (de) Antigen aus streptococcus pyogenes
ATE542829T1 (de) Impfstoff
ATE426412T1 (de) Adjuvante influenza-vakzine
WO2004030608A3 (en) Nanoemulsion vaccines
AU2001278003A1 (en) Bacteriophage having multiple host range
NO20024246D0 (no) Endret stamme av det modifiserte vacciniaviruset (Ankara MVA)
ATE320493T1 (de) Modifizierung des hepatitis b kernantigens
DK1255826T3 (da) Automatisering af proteindesign for proteinbiblioteker
ATE227134T1 (de) Chitosan-impfstoff-zusammensetzungen zur intranasalen verabreichung und anwendungen
MY125202A (en) Vaccine
WO2006042027A8 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
DE60138014D1 (de) Chimäre arterivirus-ähnliche partikel
AP2002002685A0 (en) Use of flavivirus for the expression of protein epitpoes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents
AP2003002734A0 (en) Purification of HBV antigens for use in vaccines.
DE60226175D1 (de) Mycobakterieller impfstoff
ATE335739T1 (de) Cak inhibitoren und deren verwendungen
IL156799A0 (en) Peptides having affinity for the gp120 viral protein and use thereof
DE60235223D1 (de) Streptococcus pyogenes polypeptide und entsprechende dna fragmente
EP1543838A4 (en) Vaccine against infectious CAT PERITONITIS
SG147465A1 (en) Vaccine
DK0792347T3 (da) Fremgangsmåder til fremstilling af forbedrede antigene Heliobacter sp. og vacciner omfattende samme
DE60234772D1 (de) Gruppe-b streptococcus antigene und entsprechende dna-fragmente
WO2003059252A3 (en) Use of a novel cell surface protease from group b streptococcus
DK1275638T3 (da) Kombinationspræparat til behandling af immunologiske sygdomme

Legal Events

Date Code Title Description
8364 No opposition during term of opposition